Sirolimus by Rare Partners for Beta Thalassaemia: Likelihood of Approval
Sirolimus is under clinical development by Rare Partners and currently in Phase II for Beta Thalassaemia. According to GlobalData, Phase II drugs for Beta Thalassaemia have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sirolimus’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sirolimus is under development for the treatment of beta-cell thalassemia and sickle cell disease. The drug candidate is a small molecule.
For a complete picture of Sirolimus’s drug-specific PTSR and LoA scores, buy the report here.
#Sirolimus #Rare #Partners #Beta #Thalassaemia #Likelihood #Approval